Ohta S, Yaguchi T, Okuno H, Chneiweiss H, Kawakami Y, Okano H. CHD7 promotes proliferation of neural stem cells mediated by MIF. Molecular Brain9(1):96,2016
Kinoshita T, Muramatsu R, Fujita T, Nagumo H, Sakurai T, Noji S, Takahata E, Yaguchi T, Tsukamoto N, Kudo-Saito C, Hayashi Y, Kamiyama I, Ohtsuka T, Asamura H, Kawakami Y. Prognostic value of tumor-infiltrating lymphocytes differs depending on histological type and smoking habit in completely resected non-small-cell lung cancer. Ann Oncol. 27(11):2117-2123,2016
Kudo-Saito C, Fuwa T, Kawakami Y. Targeting ALCAM in the cryo-treated tumour microenvironment successfully induces systemic anti-tumour immunity. Eur J Cancer. 62:54-61,2016
Yaguchi T, Kawakami Y. Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation. Int. Immunol.28(8):393-399,2016
Fukaya R, Ohta S, Yaguchi T, Matsuzaki Y, Sugihara E, Okano H, Saya H, Kawakami Y, Kawase T, Yoshida K, Toda M. MIF maintains the tumorigenic capacity of brain tumor-initiating cells by directly inhibiting p53. Cancer Res. In Press:,2016
Kawakami Y, Popivanova B, Nuchsupha S, Hayakawa T, Nakamura K, Nagumo H, Katano I, Kinoshita t, Tsubota k, Kamijuku h, Kawamura N, Miyazaki J, Satomi R, Sugiyama J, Nishio H, Noji S, Kudo-Saito C, Tsukamoto N, Sakurai T, Fujita T, Yaguchi T. Personalized Cancer Immunotherapy: Immune Biomarkers and Combination Immunotherapy. in “Immunotherapy of Cancer: An Innovative Treatment Comes of Age” Eds: Yoshiyuki Yamaguchi, Springer. In Press:,2015
Ogawa Y, Morikawa S, Okano H, Mabuchi Y, Suzuki S, Yaguchi T, Sato Y, Mukai S, Yaguchi S, Inaba T, Okamoto S, Kawakami Y, Tsubota K, Matsuzaki Y, Shimmura S. MHC-compatible bone marrow stromal/stem cells trigger fibrosis by activating host T cells in a scleroderma mouse model. Elife. 5. pii:e09394,2016
Matsushita M , Otsuka Y, Tsutsumida N, Tanaka C, Uchiumi A, Ozawa K, Suzuki T, Ichikawa D, Aburatani H, Okamoto S, Kawakami Y, Hattori Y. Identification of novel HLA-A*24:02-restricted epitope derived from a homeobox protein expressed in hematological malignancies.PLOS ONE. 11(1):e0146371,2016
Arato T, Daimon T, Heike Y, Ishii K, Itho K, Kageyama S, Kawakami Y, Nakayama E, Ozawa K, Sato N, Shiku H, Takeuchi M, Tani K, Tamada K, Ueda R, Yamaguchi Y, Yamanaka T, Yamaue H, Yasukawa M, Iguchi T, Kitano S, Miyahara Y, Nagata Y, Noguchi M, Terashima T, Asano T, Asonuma M, Ikeda H, Kakimi K, Takesako K, Tanaka M, Amakasu K, Yamada A, Harada N, Aoshi T, Kuroda E, Kobiyama K, Muraoka D, Yamazaki N, Kuchiba A, Tanaka S, Michimae H, Yamada T, Hanada K, Okada H, Takebe N, Hirano N, Okumura S, Sato D, Shibatsuji M, Yamaguchi T. 2015 Guidance on cancer immunotherapy development in early-phase clinical studiesCancer Sci. 106(12):1761-1771,2015
Inozume T, Yaguchi T, Furuta J, Harada K, Kawakami Y, Shimada S. Melanoma cells control anti-melanoma CTL esponses via interaction between TIGIT and CD155 in the effector phase. J Invest Dermatol. 136(1):255-63,2016